Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 20/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 19/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068705 | 0.85 | MTNR1B (0.50) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| SCHEMBL3053825 | 0.80 | MTNR1B (0.67) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL29827337 | 0.80 | MTNR1A (1.00) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL1566122 | 0.80 | MTNR1A (1.00) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29237 | 0.80 | MTNR1A (1.00) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| Ramelteon SCHEMBL29380213 | 0.80 | MTNR1A (1.00) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| (R)-Ramelteon SCHEMBL338730 | 0.80 | MTNR1A (1.00) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| SCHEMBL1612779 | 0.79 | MTNR1B (0.69) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| SCHEMBL1567202 | 0.78 | MTNR1B (0.67) | MTNR1BMTNR1AABCB11SIGMAR1USP2 | |
| SCHEMBL8474769 | 0.77 | MTNR1B (0.60) | MTNR1BMTNR1AABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| US-8183285-B2 | Therapeutic agent for irritable bowel syndrome and methods thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20100331402-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2248808-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| US-20100267821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20090048325-A1 | Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1997488-A1 | AGENT FOR PREVENTION/TREATMENT OF IRRITABLE BOWEL SYNDROME | Takeda Pharmaceutical Company Limited (JP) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267821-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | HRH4, HRH2, HRH3 | MTNR1B 34/4885MTNR1A 21/4885ABCB11 1325/4885 |
| US-20090048325-A1 | Prophylactic or Therapeutic Agent for Irritable Bowel Syndrome | HRH4, HRH2, HRH3 | MTNR1B 34/4885MTNR1A 21/4885ABCB11 1325/4885 |
| US-20170128409-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | AANAT, DBH, CHAT | MTNR1B 56/4885MTNR1A 99/4885ABCB11 1696/4885 |
| US-20100331402-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER | AANAT, DBH, CHAT | MTNR1B 56/4885MTNR1A 99/4885ABCB11 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.